Schizophrenia and MTHFR: The Methylation Connection in Psychosis Research

Schizophrenia is among the most complex and debilitating psychiatric conditions. Its genetic architecture is vast, its neurobiological underpinnings are incompletely understood, and its treatment — while meaningful for many — leaves significant unmet needs. Within this complexity, one biological thread has emerged with growing consistency: the methylation cycle, and MTHFR specifically.

The Methylation Hypothesis in Psychosis Research

The methylation hypothesis of schizophrenia proposes that impaired methylation — producing insufficient SAM and excessive homocysteine — contributes to the neurochemical dysregulation underlying psychosis. This hypothesis has gained substantial traction over the past two decades, with a body of evidence that includes elevated rates of MTHFR C677T in schizophrenia populations across multiple meta-analyses, elevated homocysteine in first-episode and chronic schizophrenia patients compared to controls, lower folate and B12 in schizophrenia patients, and associations between MTHFR variants and both positive symptoms (hallucinations, delusions) and negative symptoms (flat affect, social withdrawal).

The Mechanisms

The mechanisms are multiple and interconnected. Dopamine dysregulation in mesolimbic circuits produces positive symptoms — and methylation is required to regulate dopamine synthesis, release, and degradation via COMT. NMDA receptor hypofunction is increasingly recognised as a core feature of schizophrenia, and elevated homocysteine directly impairs NMDA receptor function. Myelin disruption from reduced methylcobalamin B12 and methylfolate impairs white matter integrity — a consistent finding in schizophrenia neuroimaging. Neuroinflammation driven by elevated homocysteine and reduced glutathione creates the inflammatory milieu increasingly implicated in psychosis research.

Clinical Implications

The research does not suggest that MTHFR causes schizophrenia, and methylation support is not a treatment for psychotic illness. What it does suggest is that addressing methylation deficiencies in people with schizophrenia — particularly those with MTHFR variants or elevated homocysteine — represents a meaningful adjunctive strategy. A randomised controlled trial published in JAMA Psychiatry found that folate supplementation improved negative symptoms in schizophrenia patients with MTHFR variants. Methylfolate — not folic acid — was the most effective form in MTHFR-positive individuals.

NeuroThrive™ products are food supplements and are not intended to diagnose, treat, or cure any medical condition. If you or someone you care for has schizophrenia, always consult a psychiatrist before making changes to nutritional supplementation.